PMID- 27753660
OWN - NLM
STAT- MEDLINE
DCOM- 20190624
LR  - 20190624
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 26
IP  - 6
DP  - 2018 Jul
TI  - Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: 
      EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well 
      to Moderately Differentiated Carcinoma.
PG  - 374-382
LID - 10.1097/PAI.0000000000000437 [doi]
AB  - Epidermal growth factor receptor 1 (EGFR) and erb-b2 receptor tyrosine kinase 2 
      (ERBB2/HER2) are frequently dysregulated in human cancers. We analyzed EGFR and 
      ERBB2 status in 105 gastric and gastroesophageal junction carcinoma and their 
      clinicopathologic features. For EGFR, 92 (88%) tumors were scored as 0, 2 (2%) as 
      1+, 7 (7%) as 2+, and 4 (3%) as 3+ by immunohistochemistry (IHC) and 4 (4%) 
      tumors showed EGFR amplification by fluorescence in situ hybridization (FISH). 
      For ERBB2, 90 (86%) tumors were scored as 0, 4 (4%) as 1+, 6 (6%) as 2+, and 5 
      (5%) as 3+ by IHC and 12 (12%) showed ERBB2 amplification by FISH. The 
      concordance rate between IHC and FISH of EGFR was 98.1% (P<0.001) and of ERBB2 
      was 93.3% (P<0.001). Most tumors with ERBB2 amplification were tubular 
      adenocarcinoma (N=11, P=0.02) and Lauren intestinal type (N=12, P=0.016). There 
      was no statistically significant difference between EGFR amplification and tumor 
      classification. EGFR amplification had significant impact on overall survival in 
      certain subgroups: early stages (stages I and II) (P<0.001), well to moderately 
      differentiated tumors (P=0.001), and fewer regional lymph node metastasis (pN1) 
      (P=0.001). ERBB2 status had little predictive value on overall survival. In 
      conclusion, this study showed ERBB2 amplification was significantly observed in 
      tubular adenocarcinoma and Lauren intestinal-type carcinoma. The IHC scoring 
      criteria for ERBB2 can be applied to EGFR. EGFR amplification had associated with 
      poor prognosis in early, well to moderately differentiated carcinoma.
FAU - Liao, Jia-Bin
AU  - Liao JB
AD  - Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General 
      Hospital.
AD  - Centre for General Education, Yuh-Ing Junior College of Health Care and 
      Management.
AD  - Kaohsiung Medical University.
FAU - Lee, Huai-Pao
AU  - Lee HP
AD  - Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General 
      Hospital.
AD  - Department of Nursing, Meiho University, Kaohsiung, Taiwan.
FAU - Fu, Hsiao-Ting
AU  - Fu HT
AD  - Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General 
      Hospital.
FAU - Lee, Herng-Sheng
AU  - Lee HS
AD  - Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General 
      Hospital.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*diagnosis/mortality/pathology
MH  - Aged
MH  - Aged, 80 and over
MH  - Cell Differentiation
MH  - ErbB Receptors/genetics/metabolism
MH  - Esophagogastric Junction/metabolism/*pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Receptor, ErbB-2/*metabolism
MH  - Stomach Neoplasms/*diagnosis/mortality/pathology
MH  - Survival Analysis
EDAT- 2016/10/19 06:00
MHDA- 2019/06/25 06:00
CRDT- 2016/10/19 06:00
PHST- 2016/10/19 06:00 [pubmed]
PHST- 2019/06/25 06:00 [medline]
PHST- 2016/10/19 06:00 [entrez]
AID - 10.1097/PAI.0000000000000437 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2018 Jul;26(6):374-382. doi: 
      10.1097/PAI.0000000000000437.